{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:37:18Z","timestamp":1793471838363,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaccao.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:12:02Z","timestamp":1755245522000},"page":"668-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular Disease in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"7","author":[{"given":"Nazanin","family":"Aghel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Howard","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jaccao.2025.06.007_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.06.007_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"Mendizabal","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","article-title":"Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.jaccao.2025.06.007_bib8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1080\/10428194.2023.2242990","article-title":"High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","volume":"64","author":"Aghel","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","article-title":"Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States","volume":"17","author":"Coutinho","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib11","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41375-018-0247-1","article-title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","volume":"32","author":"Aghel","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jaccao.2025.06.007_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee","volume":"15","author":"Januzzi","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jaccao.2025.06.007_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/heartjnl-2020-318251","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease","volume":"107","author":"Leong","year":"2021","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaccao.2025.06.007_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"R\u00e9a","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaccao.2025.06.007_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jaccao.2025.06.007_bib25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaccao.2025.06.007_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk Res"},{"issue":"20","key":"10.1016\/j.jaccao.2025.06.007_bib30","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1073\/pnas.96.20.11410","article-title":"Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling","volume":"96","author":"Heuchel","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","article-title":"Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"15","author":"Gustafson","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","author":"Agostino","year":"2011","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jaccao.2025.06.007_bib34","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jaccao.2025.06.007_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1007700629728","article-title":"Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo","volume":"13","author":"Myll\u00e4rniemi","year":"1999","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.ATV.0000128321.91782.b9","article-title":"Protective role of imatinib in atherosclerosis","volume":"24","author":"Kadowaki","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.jaccao.2025.06.007_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.8730","article-title":"Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries","volume":"18","author":"Masuda","year":"2011","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib39","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jacc.2005.07.060","article-title":"A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib","volume":"46","author":"Zohlnh\u00f6fer","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/eurheartj\/ehu035","article-title":"Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension","volume":"36","author":"Shah","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib41","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.jaccao.2025.06.007_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.jaccao.2025.06.007_bib43","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaccao.2025.06.007_bib44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.jaccao.2025.06.007_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.leukres.2011.01.021","article-title":"Nilotinib cardiac toxicity: should we still be concerned?","volume":"35","author":"Atallah","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Woodman","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jaccao.2025.06.007_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11523-016-0417-x","article-title":"Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy","volume":"11","author":"Bondon-Guitton","year":"2016","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib51","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib52","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jaccao.2025.06.007_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib54","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1038\/s41598-024-57686-8","article-title":"Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1","volume":"14","author":"Pinheiro","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2025.06.007_bib55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.jaccao.2025.06.007_bib56","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib57","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1002\/ajh.25232","article-title":"Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy","volume":"93","author":"Racil","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib58","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1152\/ajpendo.00163.2022","article-title":"Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia","volume":"324","author":"Janssen","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib59","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1093\/oncolo\/oyad225","article-title":"Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: a national population-based cohort study","volume":"29","author":"Huang","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39057-x","article-title":"Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation","volume":"13","author":"Roa-Chamorro","year":"2023","journal-title":"Sci Rep"},{"issue":"5682","key":"10.1016\/j.jaccao.2025.06.007_bib61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"27","key":"10.1016\/j.jaccao.2025.06.007_bib62","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.jaccao.2025.06.007_bib63","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jaccao.2025.06.007_bib64","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2025.06.007_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.jaccao.2025.06.007_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MCP.0b013e328338c486","article-title":"Pleural effusions due to dasatinib","volume":"16","author":"Brixey","year":"2010","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib increases endothelial permeability leading to pleural effusion","volume":"51","author":"Phan","year":"2018","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.jaccao.2025.06.007_bib69","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib70","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib71","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1183\/09031936.00035913","article-title":"Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition","volume":"42","author":"Groeneveldt","year":"2013","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.jaccao.2025.06.007_bib73","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1113\/jphysiol.2014.285304","article-title":"Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease","volume":"593","author":"MacKay","year":"2015","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1183\/09031936.00091912","article-title":"Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed","volume":"41","author":"Guignabert","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jaccao.2025.06.007_bib75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09031936.00211811","article-title":"Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries","volume":"41","author":"Nagaraj","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib77","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jaccao.2025.06.007_bib79","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.jaccao.2025.06.007_bib80","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaccao.2025.06.007_bib81","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clml.2024.01.005","article-title":"A review of the therapeutic role of bosutinib in chronic myeloid leukemia","volume":"24","author":"Kantarjian","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jaccao.2025.06.007_bib83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020936913","article-title":"Incident pulmonary arterial hypertension associated with bosutinib","volume":"10","author":"Yo","year":"2020","journal-title":"Pulm Circ"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib85","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1183\/13993003.01004-2016","article-title":"Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension","volume":"48","author":"Hickey","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib86","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1183\/13993003.01410-2016","article-title":"Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity","volume":"48","author":"Riou","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.jaccao.2025.06.007_bib88","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaccao.2025.06.007_bib89","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib90","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2025.06.007_bib91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.jaccao.2025.06.007_bib92","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.06.007_bib93","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacl.2023.05.002","article-title":"Evaluating the residual risk of recurrent cardiovascular events in contemporary cardiovascular outcomes trials","volume":"17","author":"Serge","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"14","key":"10.1016\/j.jaccao.2025.06.007_bib94","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","article-title":"Ponatinib drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1\u03b2 mediated inflammation","volume":"132","author":"Tousif","year":"2023","journal-title":"Circ Res"},{"issue":"35","key":"10.1016\/j.jaccao.2025.06.007_bib96","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaccao.2025.06.007_bib97","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib98","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaccao.2022.06.004","article-title":"Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity","volume":"4","author":"Yu","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"18","key":"10.1016\/j.jaccao.2025.06.007_bib99","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.jaccao.2025.06.007_bib100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaccao.2025.06.007_bib102","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jaccao.2025.06.007_bib103","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib104","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"10.1016\/j.jaccao.2025.06.007_bib105","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jaccao.2025.06.007_bib106","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.06.007_bib107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-137613","volume":"136","author":"Mauro","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaccao.2025.06.007_bib108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.htct.2020.04.009","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring","volume":"43","author":"Seguro","year":"2021","journal-title":"Hematol Transfus Cell Ther"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:41:55Z","timestamp":1783582915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325002509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666087325002509"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.06.007","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Disease in Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}